2nd Quarter - Amendment
THE MCMANUS GROUP for PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA
Firm
Income
$80,000
Expenses
—
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 2nd Quarter - Report | Jul 20, 2020 | $80,000 | Replaced |
| 2nd Quarter - Amendment | Jan 11, 2022 | $80,000 | Replaced |
| 2nd Quarter - Amendment (this page) | Aug 29, 2022 | $80,000 | Yes |
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
Access and reimbursement in Parts B & D. Part D redesign. Lobbied against the International Pricing Index model (83 FR 54546).
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN MCMANUS | — |
| ALANNA TEMME | LD, Rep. Jon Porter |
Health Issues HCR
Reforms related to the pharmaceutical supply chain.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN MCMANUS | — |
| WILLIAM RHYNE | — |
| ALANNA TEMME | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.